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Long QT syndrome (LQTS) is an inherited channelopathy
that causes sudden death in all ages owing to polymorphic
ventricular tachycardia. Although it is uncommon, individuals
affected by certain LQTS mutations present in utero with
ventricular tachycardia with or without second-degree atrio-
ventricular block (AVB). Fetuses manifesting these rhythms
are at risk of intrauterine heart failure and fetal demise.1
Fetal LQTS can be suspected by echocardiography but is
diagnosed by fetal magnetocardiography (fMCG), which can
be performed from mid-second trimester to term.2 Findings
of a prolonged corrected QT interval (QTc) and the distinct
characteristics of torsades de pointes (TdP) in a fetus with
ventricular tachycardia (VT) and either sinus bradycardia or
second-degree AVB conﬁrms the clinical suspicion of
LQTS. Transplacental antiarrhythmic drug administration
is effective for rescuing fetuses that have developed, or are at
high risk of developing, fetal hydrops.3 fMCG can also
monitor transplacental antiarrhythmic drug treatment given
to rescue the fetuses. The purpose of this report is to describe
the treatment of 2 LQTS fetuses with hydrops and complex
arrhythmia guided by fMCG.Case reports
Case 1
A 32-year-old woman in the 28th week of her ﬁfth pregnancy
was referred to our institution with a 3-week history of fetal
bradycardia (fetal heart rate 60 beats per minute [bpm]). She
had no personal or family histories of cardiac arrest, seizures,
or syncope. Of her 4 pregnancies, only 1 had ended in aKEYWORDS Congenital long QT syndrome; Ventricular arrhythmia; Prenatal
management; Ventricular tachycardia/torsades de pointes; Fetal magneto-
cardiography (Heart Rhythm Case Reports 2016;0:1–5)
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tion revealed a structurally normal heart with normal size,
normal function, and second-degree AVB (V rate 60 bpm,
atrial rate 120 bpm). Her antibody screen was negative for
anti-SSA and anti-SSB antibodies. One week later, a follow-
up fetal echocardiogram showed a ventricular rate of 220
bpm (atrial rate was 130 bpm) (Figure 1A). An fMCG was
then performed which revealed nonsustained VT alternating
with sinus rhythm (rate 130 bpm) (Figure 1B). The VT was
present about 75% of the time. The QTc was 591 ms
(Figure 1C).
Over the ensuing days, the TdP continued and the fetus
developed severe hydrops. We therefore decided to admin-
ister an intravenous loading dose of magnesium (4 g)
followed by a continuous infusion (1–1.4 g/h) to maintain
a maternal serum level of 1.2–1.4 (normal ¼ 0.65–1.05
mmol/L). The mother’s baseline magnesium level was 0.72
mmol/L. Within 3 days of magnesium infusion the frequency
of TdP decreased (by fMCG the fetus was in sinus rhythm
80% of the time). Because of the concern for an SCN5A
R1623Q mutation, we began treatment with mexiletine (600
mg orally per day). The fetus remained in sinus rhythm (rate
100 bpm) with continuous magnesium infusion and oral
mexiletine given to the mother. At 35 weeks the fetus
became bradycardic and was found to be in second-
degree AVB.
The mother underwent an elective cesarean section at 35
weeks’ gestation and a 2334-g male infant was delivered.
The heart rate at birth was 56 bpm owing to functional
second-degree AVB with 2:1 conduction (Figure 2A).
Immediately after delivery, temporary transvenous pacing
wires were placed. On the second day of life, a permanent
pacemaker was implanted. We also administered oral
mexiletine (4 mg/kg/d) and intravenous propranolol (0.02
mg/kg/h); no VT was observed. On the 14th day of life, the
infant’s electrocardiography showed sinus rhythm with a left
bundle branch block pattern (Figure 2B). On the 40th day of
life, the mexiletine blood levels declined, and TdP occurredpen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2016.09.001
KEY TEACHING POINTS
 In severe cases of congenital long QT syndrome
(LQTS), ventricular tachycardia / torsades de
pointes during fetal life can cause fetal hydrops.
 Fetal magnetocardiography proved useful for not
only diagnosing the fetal arrhythmia but
monitoring the fetal heart rhythm during fetal
treatment.
 Two hydropic fetuses with LQTS with ventricular
arrhythmias and heart block were successfully
managed in utero.
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neously terminated.
The VVI pacing rate was increased to 110 bpm. When the
infant was at the age of 5 months, weighing 6.6 kg, we placed
an implantable cardioverter-deﬁbrillator (ICD). The shock
lead was implanted subcutaneously through the left thor-
acodorsal region, and the generator was placed under the
right abdominal rectus muscle (Figure 2C). Following
implantation of the ICD, the child did not experience any




Figure 1 Case 1. A: At 29 weeks, a fetal echocardiogram showed ventricula
compared with an atrial rate of 130 bpm. B: Fetal magnetocardiography (fMCG) rev
during sinus rhythm.follow-up. He received oral mexiletine (12 mg/kg/d) and
propranolol (2 mg/kg/d).
Genetic testing of this case revealed a KCNH2 missense
mutation (S624R). To date, there has been no functional
analysis of this mutation. His mother’s QTc was 440 ms, and
his father’s was 390 ms. Neither of the parents had any
mutation in this locus. However, we did not exclude parental
germinal mosaicism.Case 2
A 35-year-old woman was referred to our institution at 24
weeks’ gestation because of a fetal pericardial effusion and
fetal tachycardia. The family history was positive for a
paternal KCNH2 missense mutation (T613M) diagnosed
after a syncopal episode. The fetal echocardiogram revealed
a peristent tachycardia with atrioventricular dissociation
(Figure 3A). The fMCG conﬁrmed the clinical diagnosis of
VT with a rate of 220 bpm (Figure 3B) with a prolonged (511
ms) QTc during brief (o20% of the recording time) episodes
of sinus rhythm (rate 110–120 bpm) (Figure 3C). The mother
was admitted to the hospital for continuous intravenous
magnesium treatment to terminate the fetal VT. However,
despite maternal serum magnesium levels of 1.28 mmol/L
(normal range 0.65–1.05 mmol/L), the VT persisted and the
fetus became hydropic (Figure 3D). Ten days after the(QTc=591ms)
C
r tachycardia (VT) with a ventricular rate of 220 beats per minute (bpm),
ealed polymorphic VT. C: fMCG showed a prolonged QT interval (591 ms)
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dose 60–120 mg orally per day), following which the VT
resolved. We continued magnesium by a continuous infusion
(1.4 g/h) after we started propranolol. fMCG revealed a
decreased fetal sinus rate from 120 to 110 bpm. The hydrops
then improved gradually. The mother’s daily total heart beats
decreased from 129,108 to 103,206 (average heart rate
decreased from 90 to 71 bpm) after propranolol adminis-
tration, indicating beta-adrenergic blocking effect. Subse-
quently, the fetal sinus rhythm (rate 110 bpm) was
maintained. A 2010-g female infant was delivered by
elective cesarean delivery at 37 weeks’ gestation. After
birth, the infant’s electrocardiography showed an intermit-
tent left bundle branch block pattern. On the ﬁfth day of life,
she developed second-degree AVB with a ventricular rate of
60–80 bpm and metabolic acidemia owing to poor cardiac
output. She urgently underwent temporary epicardial ven-
tricular pacing lead implantation. At the age of 3 months,
sustained VT occurred immediately after permanent pace-
maker implantation and was successfully terminated by
cardioversion. Hypokalemia (serum potassium level was
2.9 mmol/L) during intensive care likely contributed to the
VT. VT did not recur after the potassium was corrected. Her
genetic testing identiﬁed the KCNH2 missense mutation
(T613M), identical to that of her father. She received oralFigure 2 Case 1. A: The infant’s heart rate at the time of birth was 56 beats per
life, the electrocardiogram showed a sinus rhythm with a left bundle branch block
was implanted.mexiletine (7 mg/kg/d) and propranolol (3 mg/kg/d) with
pacing (VVI 110 bpm) for 23 months.Discussion
In rare severe cases of congenital LQTS, VT/TdP or the
combination of TdP and second-degree AVB during fetal life
can cause fetal hydrops and intrauterine fetal demise.4 We
report the successful intrauterine management of 2 fetuses
with ventricular arrhythmias and hydrops. Both had KCNH2
mutations in the pore region.5 But effective intrauterine
management was different.
Fetal-onset LQTS is a rare and difﬁcult-to-diagnose
condition. In utero, the fetal presentation of LQTS can
manifest as a reduced baseline fetal heart rate o3rd
percentile for gestational age or 2 standard deviations below
the mean for normal fetuses.1 In more severe cases,
ventricular tachycardia, second-degree AVB, and hydrops
may be present.6 Fetal LQTS has been successfully diag-
nosed by fMCG.2 In the present cases, fMCG proved useful
for revealing the fetal arrhythmia and determining the
correction of the fetal QT interval.
Intervention should be considered for fetal hydrops
attributable to TdP or sustained VT. There are 2 types of
intervention: delivery or fetal therapy. Intrauterine man-minute (bpm), and he had a 2:1 atrioventricular block. B: On the 14th day of
pattern. C: At the age of 5 months, an implantable cardioverter-deﬁbrillator
Figure 3 Case 2. A: At 24 weeks’ gestation, the initial fetal echocardiography showed fetal ventricular tachycardia with a ventricular rate of 187 beats per
minute (bpm) and an atrial rate of 123 bpm. B: Fetal magnetocardiography (fMCG) revealed sustained ventricular tachycardia with a V rate of 220 bpm.
C: fMCG showed a prolonged QT interval (511 ms) during transient sinus rhythm. D: At this time, the fetus also developed ascites, skin edema, and pericardial
effusion as symptoms of severe hydrops.
Heart Rhythm Case Reports, Vol 0, No 0, Month 20164agement of the fetus with LQTS can control the potentially
lethal ventricular arrhythmias and postpone delivery, thus
avoiding ICD or pacemaker implantation in a premature
infant and other morbidities of prematurity. A few previous
reports have detailed the fetal treatment in such cases, but
the effective drugs differed between the reports and a
consensus regarding appropriate drug selection has not yet
been established.3 In case 1, magnesium was effective for
the ventricular ﬁbrillation/TdP. Magnesium has success-
fully restored sinus rhythm in several case reports,7 but in
our second case beta-blockers were effective for the
sustained VT. Magnesium not only reduced the occurrence
of 1 type of early afterdepolarization but also abolished it,
providing an insight into the mechanism of TdP.8 Beta-
blockers have a transplacental transfer rate of only 25%–
30%, and their therapeutic effect for TdP is limited.1
However, Chang et al9 described successful transplacental
therapy for VT using a beta-blocker. In our case, the fetal
heart rate during sinus rhythm decreased from 120 to 110
bpm during treatment with propranolol, which may indi-
cate drug effect despite the unfavorable pharmacokinetics.Transplacental antiarrhythmic drug administration is an
effective treatment for the rescue of fetuses that have
developed or have a high risk of developing fetal hydrops.
However, the selection of the appropriate drugs in these
cases has not yet been established and requires further
study.Conclusion
Severe cases of LQTS presenting during fetal life with VT/
TdP and hydrops can be successfully treated in utero.
Historically, and in the ﬁrst case described here, intravenous
magnesium given to the mother has a high likelihood of
terminating VT/TdP. But if magnesium fails, other treat-
ment, including transplacental propranolol, can be consid-
ered and would be preferable to the preterm delivery of a
hydropic newborn.References
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